Specialty Pulp and Paper Chemicals Market Advanced Research And Growth Opportunities In Global Industry By 2023

Specialty Pulp and Paper Chemicals Market

Specialty Pulp and Paper Chemicals Market

Specialty pulp and paper chemicals are the raw materials used to produce specialty paper and it reduces the consumption of water and energy.

PORTLAND, OREGON, UNITED STATES, December 1, 2020 /EINPresswire.com/ — According to a new report published by Allied Market Research, titled, "Specialty Pulp and Paper Chemicals Market by Type: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global specialty pulp and paper chemicals market was valued at 15,568 million in 2016, and is projected to reach 22,829 million by 2023, registering a CAGR of 5.6% from 2017 to 2023. In 2016, the functional chemicals segment accounted for approximately one-fifth share of the global market, in terms of value.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/4586

Specialty pulp and paper chemicals are the raw materials used to produce specialty paper. These are the integral part of manufacturing process of paper and reduces the consumption of water and energy. It also improves the optical and functional properties of paper such as color, texture, brightness, strength, printing ability, and others during the paper manufacturing process. Some of the specialty paper chemicals include sodium hydrosulfite, hydrogen peroxide, and chlorine, which are used as bleaching agents; sodium silicate, enzymes and various surfactants used in the de-inking process; and alkyl ketene dimer and alkenyl succinic anhydride used for sizing. Specialty paper has wide applications, which includes printing, labeling, and packaging in various sectors such as paper, food, textile, retail, and packaging.

The recycling of paper has gained considerable importance in the global paper industry over the past decade. The increased use of recycled paper results in an increased requirement for specialty pulp and paper chemicals. In addition, the demand for functional chemicals in various applications such as packaging, printing, and decoration is on an increase, thus driving the specialty pulp and paper chemicals market.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4586

The functional chemicals segment of specialty chemicals comprises of different types of dry-strength additives, wet-strength resins, fluorescent whitening, and sizing agents. The wide applications of specialty paper in different sectors demand different characteristics of papers related to its color, brightness, sizing, texture, and others. The use of functional chemicals has increased to meet the needs of the paper manufacturing industry, which contributes to the growth of the specialty pulp and paper chemicals market. However, due to the adverse effects of chemicals on environment and human health stringent regulations are drafted over their usage in manufacturing of specialty paper, which hampers the growth of the market. In addition, fluctuations in the price of raw materials and chemicals required for paper production is expected to restrict the growth of the specialty pulp and paper chemicals market.

Nevertheless, specialty pulp and paper chemicals offer benefits such as improvement in productivity, reduced water, raw materials, and energy consumption that help control the overall cost of operation providing lucrative opportunities for the market in the upcoming years. Moreover, the use of new enzymes in the production of specialty papers is also anticipated to provide great opportunities for the specialty pulp and paper chemicals market during the forecast period.

Interested in Procuring this Report? Visit: https://www.alliedmarketresearch.com/specialty-pulp-and-paper-chemical-market/purchase-options

Key Findings of the Specialty Pulp and Paper Chemicals Market:

• The functional chemical segment is expected to be fastest-growing segment, at an estimated CAGR of 6.3% from 2017 to 2023.
• The bleaching & RCF chemical segment is expected to account for the highest market share and is anticipated to grow at a CAGR of 5.0% from 2017 to 2023.
• Asia-Pacific accounted for largest market share in the global specialty pulp and paper chemicals growing at a CAGR of 7.4%.
• In 2016, the U.S. accounted for the largest market share growing at a CAGR of 4.1%, closely followed by China, which is growing at an estimated CAGR of 7.9% from 2017 to 2023.
• LAMEA is anticipated to grow at a significant CAGR of 5.8%.

In terms of value, Asia-Pacific and LAMEA collectively contributed more than half of the share in the global market in 2016.
The key players operating in specialty pulp and paper chemical market are AkzoNobel N.V., Ashland Inc., Buckman Laboratories International, Inc., BASF SE, Buckman Laboratories International, Inc., Kemira Oyj, SNF Floerger, The Dow Chemical Company, Evonik Industries AG, Nalco Holding Company and Shell Chemicals.

Get detailed COVID-19 impact analysis on the Specialty Pulp And Paper Chemical Market: https://www.alliedmarketresearch.com/request-for-customization/4586?reqfor=covid

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Meningococcal Vaccines Market analysis, size, share, Covid-19 scenario, Global industry Forecast till 2026

Meningococcal Vaccine Market

Meningococcal Vaccine Market

The global Meningococcal Vaccine Industry is projected to garner $4.19 billion by 2026, witnessing a CAGR of 9.5% from 2019 to 2026.

Increase in outbreaks of meningococcal disease, surge in immunization programs across the globe, and rise in research and development for vaccine technology.”

— Ashish

PUNE, MAHARASHTRA, UNITED STATES, December 1, 2020 /EINPresswire.com/ — The global Meningococcal Vaccine Industry garnered $1.93 billion in 2018, and is projected to garner $4.19 billion by 2026, witnessing a CAGR of 9.5% from 2019 to 2026. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. "Meningococcal Vaccine Market by Serogroup (MenACWY, MenB/BC, MenC, MenAC, and MenA), Vaccine Type (Conjugate, Polysaccharide, and Subcapsular), and End User (Pediatric, Adults, and Travelers): Global Opportunity Analysis and Industry Forecast, 2018–2026."

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/330

Rise in outbreaks of meningococcal disease, increase in immunization programs across the world, and surge in research and development for vaccine technology drive the global meningococcal vaccine market

Covid-19 scenario

Due to lockdown, immunization programs will come to a halt and program schedules will be changed in various countries.

Research and development activities for vaccine technology will be limited, as researchers need to stay at home during the lockdown.

Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.

Get detailed COVID-19 impact analysis on the Meningococcal Vaccine Market @ https://www.alliedmarketresearch.com/request-for-customization/330?reqfor=covid

Based on vaccine serotype, the majority of share was contributed by MenACWY vaccine segment. It accounted for nearly half of the total share in 2018, and is estimated to maintain its lead position during the forecast period. However, the MenA vaccine segment is anticipated to grow at the highest CAGR of 13.5% during the forecast period.

The conjugate segment to maintain its lead by 2026

Based on vaccine type, the conjugate segment held the largest share of the global meningococcal vaccine market, accounting for nearly half of the total market share in 2018, and is estimated to maintain its lead by 2026. Moreover, this segment is estimated to grow at the highest CAGR of 10.2% from 2019 to 2026. This is attributed to usage of vaccines in routine immunization schedules, preventive campaigns, and outbreak responses. The research also analyzes segments including polysachharide and subcapsular.

Leading market players

Bio-Manguinhos
Bio-Med Pvt. Limited
Chongqing Zhifei Biological Products Co., Ltd.
GlaxoSmithKline Plc
Hualan Biological Engineering Inc.
Incepta Pharmaceuticals Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.
Walvax Biotechnology Co., Ltd.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/330

Based on region, North America accounted for the largest market share in terms of revenue in 2018, holding nearly half of the global meningococcal vaccine market, and is estimated to maintain its lead position throughout the forecast period. This is due to surge in prevalence of meningitis disease and ease in availability of meningococcal vaccine products for treatment of the disease. However, Asia-Pacific is expected to portray the largest CAGR of 14.7% from 2019 to 2026, owing to surge in outbreaks of meningococcal diseases and widespread availability of products.

Similar Reports:

Orthopedic Devices Market Global Opportunity and Industry Forecast, 2026

Cancer Biomarkers Market Global Opportunity & Industry Forecast, 2027

COPD and Asthma Devices Market Global Opportunity & Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
+19049962983 ext.
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Protein Expression Market To Grow Valuation $4.61 Billion By 2026, At CAGR Of 10.2% | Protein

Protein Expression

The growth in protein expression market is due to rise in prevalence of chronic disease such as diabetes, cancer, autoimmune disorders & cardiovascular diseases

pharmaceutical companies are significantly investing in R&D expenditure thereby propelling the market growth.”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, December 1, 2020 /EINPresswire.com/ — Protein expression is defined as a biotechnological procedure, which includes generation of precise proteins. These proteins are formed through manipulation of gene expression in organisms of interest. The procedure leads to expression of large amounts of recombinant gene in organisms. Furthermore, this has led to many possibilities of expression and isolation of heterologous proteins for research, clinical, and industrial purposes. This, in turn, has led to advancements in genetic engineering and recombinant technologies. Significant advancements in the field of biotechnology have enabled expression and isolation of recombinant proteins on large scale. Some of products which are used to perform protein expression present in the market include reagents, expression vectors, competent cells, instruments, and others. These products are used in designing therapeutics and conducting research related to medicines.

The global protein expression market is expected to reach $4.61 billion by 2026, registering a CAGR of 10.2% from 2018 to 2026, in terms of value.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/6463

The factors that boost the growth of the protein expression market include surge in geriatric population and increase in prevalence of chronic diseases such as cancer. Moreover, increase in spending on protein research also fuel the growth of the protein expression market. However, high monetary inputs associated with the production of protein products restrict the growth of the market. In addition, significant shortage of trained healthcare professionals and lack of local expertise also restrains the market. Conversely, emergence of microfluids, along with growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The Covid-19 outbreak has severely affected every sector across the world. The patient numbers have been increasing every day and the majority of the countries are in complete lockdown. This has affected the supply chain and overall business operations. International trading has taken a significant downfall and has created uncertainty in the stock market. These factors have affected the protein expression market.

The protein expression report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/6463

The global protein expression market is segmented based on product, application, and region.

• Based on product, the market is bifurcated into reagents, expression vectors, competent cells, instruments, and services.
• By application, it is divided into therapeutic, industrial, and research.
• Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Access Full Report @ https://www.alliedmarketresearch.com/protein-expression-market-A06098

The Major Key Players Are:

Agilent Technologies, Inc, Becton, Dickinson & Company, Bio Rad Laboratories, GenScript Biotech Corporation, LifeSensors Inc., Merck KGaA, Promega Corporation, QIAGEN N.V., Takara Holdings Inc. and Thermo Fisher Scientific Inc.

Similar Reports:

CHF Treatment Devices Market Analysis and Industry Forecast, 2027

Smart Syringes Market Analysis and Industry Forecast, 2027

Nuclear Medicine Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Direct Fed Microbial Market is Generating Revenue of $1.77 Billion by 2026, at CAGR 7.5% Growth Rate

Direct Fed Microbial

The demand for direct-fed microbial is on a rise, owing to surge in awareness toward improvement of animal health worldwide.

Rise in animal healthcare expenditure leads to easy availability of direct-fed microbial, which fuels the market growth”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, November 30, 2020 /EINPresswire.com/ — The global direct fed microbial market size was valued at $980 million in 2018, and is expected to reach $1,772 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

Direct-fed microbial contains live bacterial strains that help in the growth and development of animals. These beneficial organisms are replacing the use of antibiotics. However, due to the risk of development of antimicrobial-resistant organisms, the use of antibiotics as growth promoters for animal production has been banned. The administration of direct-fed microbial help to enhance the meat and milk production in animals such as cattle and poultry. In addition, these products modulate the immune response of animals and inhibit the growth of pathogenic organisms in the gastrointestinal tract of animals.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/6494

Increase in demand for meat & milk consumption and rise in profitability at same cost are the major factors driving the market growth of direct fed microbial market. Furthermore, significant surge in human population and increase in demand for protein content in the diet propel the market growth for direct-fed microbial. In addition, probiotics aid nutrient absorption by breaking down the complex compounds, which, in turn, helps to reduce the cost of animal production and increases the profitability of the animal producers. However, enforcement of stringent regulations regarding the vigorous usage of these microorganisms in animal diet and increase in cost of production are the major factors hampering thedirect fed microbial market growth. Conversely, ban on the usage of antibiotics in animal diet in the developed nations such the U.S., Germany, and the UK and rise in animal health concerns are anticipated to offer remunerative opportunities for market expansion in the near future.

The direct fed microbial report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.

By product, the lactobacillus segment accounted for 62% of the total direct fed microbial market share in 2018, and is expected to exhibit a prominent growth rate in the near future, owing to its increased usage in the livestock diet. Lactobacillus is the most widely used probiotics in the livestock diet, as it is considered safe and more beneficial as compared to the other bacterial species.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/6494

By livestock, the poultry segment dominated the direct fed microbial market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that poultry is the most consumed animal meat across the globe. Furthermore, individuals prefer poultry other than other livestock animals.

By region, North America accounted for the major direct fed microbial market share in 2018 and is expected to continue this trend, owing to easy availability of direct fed microbial products. Moreover, surge in the demand for probiotics and rise in awareness towards maintenance of healthy lifestyle in the region are the major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of direct fed microbial.

The Major Key Players Are:

Koninklijke DSM N. V, Bio-Vet, Archer-Daniels-Midland Company, CHR. Hansen A/S, E. I. Du Pont De Nemours And Company, Novozymes A/S, Kemin Industries, Inc., BASF SE (BASF Corporation), Evonik Industries Ag, and Adisseo.

Access Full Report @ https://www.alliedmarketresearch.com/direct-fed-microbial-market-A06129

Similar Reports:

Anti-Counterfeit Packaging Market Analysis and Industry Forecast, 2027

mHealth Market Analysis and Industry Forecast, 2027

Syphilis Testing Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

K12 INC. INVESTORS WITH LOSSES GREATER THAN $100,000 ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C.

Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C.

Securities Investigation On Behalf Of Investors Of K12 Inc. Who Have Suffered Significant Losses

NEW YORK, USA, November 30, 2020 /EINPresswire.com/ — PHILADELPHIA, Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of K12 Inc. (“K12” or the “Company”) (NYSE: LRN) to determine whether the Company engaged in securities fraud or other unlawful business practices.

INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE SECURITIES OF K12 BETWEEN APRIL 27, 2020 AND SEPTEMBER 18, 2020, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $1000,000 ARE ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C., MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, SECURITIES@KEHOELAWFIRM.COM, TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

A class action lawsuit has been filed seeking to recover damages on behalf of K12 investors who purchased, or otherwise acquired, the securities of K12 during the Class Period and suffered losses.

According to the class action complaint, K12, allegedly, made false and misleading statements to the public throughout the Class Period and failed to disclose that (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; (4) and K12’s officers lacked a reasonable basis for their positive statements about the Company’s business, operations, and prospects.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.

Michael Yarnoff, Esq.
Kehoe Law Firm, P.C.
+12157926676
info@kehoelawfirm.com


Source: EIN Presswire

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Neurologist, Dr. Paul Elliott is pleased to announce that he has devoted nearly two very productive decades of work at the Epilepsy Foundation of Florida

STUART, FL, UNITED STATES, November 30, 2020 /EINPresswire.com/ — Neurologist, Dr. Paul Elliott is pleased to announce that he has devoted nearly two very productive decades of work to aid the collective efforts of the medical and scientific professionals at the Epilepsy Foundation of Florida.

The Epilepsy Foundation of Florida is just one chapter in a national network of charitable organizations that provide services and programs for those who are dealing with epilepsy across the nation. These services include education on the science of epilepsy, its treatment, and ways an epileptic can better cope with this condition.

These services include a 24/7 help line, community forums, a children’s activity program, seizure education, the “My Seizure Diary” free self management tool advocacy, support for sudden unexpected death in epilepsy (SUDEP) support, a wellness institute, and research.
As a board certified Occupational and Neurological Medicine. Dr. Paul Elliott has been a valuable asset to the foundation in the areas of research, education, and advocacy.

Dr. Paul Elliott has worked closely with the experts at the Epilepsy Foundation of Florida to curate a robust research library and network that encompass the spectrum of discovery from concept to development. Dr. Paul Elliott has helped the Foundation to foster the development of new research professionals to support fresh avenues of discovery which will lead to better quality care and treatments.

In the area of advocacy, Dr. Paul Elliott has been invaluable with his in depth knowledge of neurobiology and occupational medicine. Because he has published and presented scientific studies in Neurological Medicine, occupational medicine, and Osteopathy, his advocacy has come with a depth and breadth of knowledge and authority which make his efforts eminently valuable.

Likewise, in the foundation’s educational efforts, Dr. Paul Elliott has been a great resource. While scientific knowledge of the brain is far from complete, Dr. Paul Elliott’s expertise and dedication to the cause have brought valuable insights to many people struggling with epilepsy, the friends and families of those living with epilepsy, those who directly care for someone living with the condition, and for many professionals who provide care and treatment for the condition.

Dr. Paul Elliott’s contributions in time and donations to the foundation have also been instrumental in the progress of the foundation’s Wellness Institute. This organization is dedicated to the prospect that those who live with epilepsy are entitled to the fullest and most productive life possible.

Today, Dr. Paul Elliott continues to provide Adult Neurological Consultation and Diagnostic Testing for patients dealing with a host of conditions and has been praised highly by both his peers and patients.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Biologics Industry To Recover From COVID-19 Crisis At 15% CAGR

Biologics Market Report 2020-30: COVID-19 Impact And Recovery

Biologics Global Market Report 2020-30: COVID-19 Impact And Recovery

The Business Research Company’s Biologics Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, November 30, 2020 /EINPresswire.com/ — Avail up to 50% off on ALL research reports at: https://www.thebusinessresearchcompany.com/global-market-reports. Offer applies until Dec 31st.

Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease that have limited treatment options. According to a biologics market overview by TBRC, there has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab (Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.

The biologics market report covers sales of biologics and related services by entities that produce biologics to treat and prevent various microbial diseases and cancers. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and a combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods.

Due to the worldwide supply and demand failures of drugs due to the COVID-19 outbreak, the global biologics market size is expected to decline from $269.2 billion in 2019 to $239.2 billion in 2020 at a compound annual growth rate (CAGR) of -11.2%. Biologic drug shortages because of an inadequate production of biologics is hampering the market growth. This inadequate or slowed production is due to the restrictions imposed by governments of various countries to shutdown factories or function with minimal staffing to contain the spread of virus and keep the staff safe. The market is then expected to recover and grow at a CAGR of 15% from 2021 and reach $464.7 billion in 2023.

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Pharmaceuticals Market – By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Pharmaceutical Drugs And Biologics Logistics Market – By Type (Cold-Chain Logistics And Non-Cold Chain Logistics), And By Region, Opportunities And Strategies – Global Forecast To 2021
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

SVHI PRP Therapy Announces New Online Consult Option for PRP for Hair Loss in the Bay Area

PRP Therapy for Hair Loss for Bay Area

PRP for hair near me

SVHI PRP Therapy offers "platelet rich plasma" treatment for hair loss using industry-standard techniques.

Our online consultation makes the first encounter very easy for our potential clients.”

— Miguel Canales

SAN MATEO, CALIFORNIA, USA, November 30, 2020 /EINPresswire.com/ — SHVI PRP Therapy, a Bay Area clinic focused on treatments for PRP (Platelet Rich Plasma) hair loss therapy at https://svhi-prp.com/, is proud to announce a new online option for the initial consultation for any patient who is searching for PRP for hair loss near them. Many patients are using the "work at home" trend to upgrade their hair, including using PRP for hair loss. They often use the common search for "PRP therapy for hair loss near me" as they try to find a best-in-class PRP for hair loss clinic in the area near Foster City, San Mateo, and Burlingame, California.

"Our online consultation makes the first encounter very easy for our potential clients," explained Miguel Canales, surgeon, and founder of SVHI PRP therapy. "PRP is just one option for hair loss therapy, and by meeting with the client over the Internet we can discuss not just PRP for hair loss but other options including hair transplantation. It makes it easy to find the best step for a man or woman's hair loss mitigation strategy."

Bay Area residents can book an online or a face-to-face appointment to discuss PRP for hair loss at https://svhi-prp.com/contact/. In addition, those who want to learn more about PRP therapy can visit the robust information page at https://svhi-prp.com/faq/ which contains newly updated information for November, 2020.

Indeed, men or women who want to look their best should extend their efforts beyond their hair and look at skincare issues; yet another website at https://svaestheticderm.com/ touches on these issues. Regardless of whether the issue is hair or skin, Dr. Miguel Canales offers no obligation consultations in the online format, where he can work with a patient, whether male or female, to improve their appearance.

ABOUT SVHI PRP THERAPY

SVHI PRP Therapy (https://svhi-prp.com/) is a Bay Area company based in Foster City, California that offers PRP for hair loss to clients from San Francisco to San Mateo, Palo Alto to Redwood City, Redwood City to Burlingame and beyond. Clients who are suffering from hair loss and are seeking innovative therapy come to SVHI PRP Therapy to explore their options, including PRP therapy for hair loss. The company offers a no-obligation consultation on hair loss with Dr. Miguel Canales, a recognized specialist in the hair loss industry, including hair transplantation.

Jason McDonald
JM Internet Group
+1 415-655-1071
email us here


Source: EIN Presswire

Los Angeles' New Med Spa Dr. Refresh Launches In-Home Aesthetic, Cosmetic and Wellness Packages for Groups

Dr. Refresh Team

Dr. Refresh Team

Dr. Refresh In-Home Services

Dr. Refresh In-Home Services

Dr. Refresh In-Home Services

Dr. Refresh In-Home Services

**Give the Gift of Wellness for the Holidays**

LOS ANGELES , CALIFORNIA , UNITED STATES , November 30, 2020 /EINPresswire.com/ — Dr Refresh the newly opened Los Angeles wellness med spa which launched this past summer is expanding to offer in-home services for popular aesthetic, wellness and recovery treatments. Considered an essential business in the era of COVID, Dr. Refresh’s new on-call and at-home services will bring the spa to one’s home and will feature Dr. Refresh’s 30 wellness and recovery treatments, as well as cosmetic enhancements for planning one’s best self for the holidays. Also related to the holidays, the Dr. Refresh team will be expanding offerings to offer rapid antigen nasal swab testing conducted by a nurse. The tests are 93% accurate and will provide results in around three minutes for a greater piece of mind during the holiday season.

With wellness at the forefront of 2020, Dr. Refresh’s new in-home services will also include hostess packages aimed to take holiday hosting to a socially distanced next level. Some of Dr. Refresh’s most popular offerings have been made accessible for in-home treatments and include IV Vitamin Infusions, Acupuncture, Lymphatic Drainage, Facial Injections, Body Contouring (cellulite reduction), Cupping, Herbology, Body Massage, select cosmetic treatments and more.

Also just in time for the holidays, the Dr Refresh team has created The COVID Refresh treatment which will have you looking your best for the new year. The COVID Refresh features a Zoom-tech neck treatment (to have you looking your best at all angles on Zoom), cryoskin body sculpting (to take off that “COVID 15”) and Dr. Refresh’s premium IV vitamin drip services to give your immune system a much needed boost.

Individuals interested in giving the gift of wellness this holiday season can receive information at DoctorRefresh.com and via 323.834.1333. Black Friday deal packages are extended through the first week of December. Gift cards are also available – For Dr. Refresh gift cards customers will receive a $50 credit for every $200 spent.

*Dr. Refresh’s at-home services are limited to the Los Angeles area.

About Dr. Refresh:
Dr. Refresh is a collection of wellness centers that curate the best of wellness, aesthetics and recovery. With one’s health at the forefront, the Dr. Refresh team blends western and traditional Chinese medicine, as well as cosmetic enhancements in partnership with surgeon Dr. Edmund Fisher. With a wellness center in Los Angeles and additional planned in 2021 at the Resort World development in Las Vegas, Dr. Refresh facilities provide sought after treatments with highlights including Vitamin IV Drip Infusion Therapy, Acupuncture, Lymphatic Drainage, Facial Injections, Body Contouring (cellulite reduction), Cupping, Herbology, Body Massage, as well as additional sought after treatments.

Jason Wanamaker
Dr. Refresh
+1 310-923-6547
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

R3 Stem Cell International Now Offering Stem Cell and Exosome Therapy Promotion for Canada

Stem Cell Therapy in Canada

best stem cell company

Best Stem Cell Clinic Canada

The US and International leader in regenerative therapies, R3 Stem Cell, is now offering Canada a promotional special for stem cell and exosome therapies.

Patients from Canada receive quality stem cell biologics with high cell counts for extremely affordable pricing at R3 International, and now 50 billion exosomes for free!”

— David Greene, MD, MBA

SCOTTSDALE, ARIZONA, USA, November 30, 2020 /EINPresswire.com/ — The US and International leader in regenerative therapies, R3 Stem Cell, is now offering Canada a promotional special for stem cell and exosome therapies. This includes a free 50 billion exosome therapy for each procedure over 50 million stem cells.

The procedures have shown to be extremely helpful for many medical conditions, including orthopedic, autoimmune, neurologic, autism, organ failure and for anti aging as well. R3 International has special stem cell programs for those with autism, kidney failure, COPD, post-stroke, diabetes and more.

R3 Stem Cell’s Centers have performed over 15,000 procedures in the past eight years. In that time, no patients have experienced a significant adverse event, with patient satisfaction exceeding 85%.

Patients have been treated from all Canadian cities, big and small. This includes Montreal, Toronto, Vancouver, Ottawa, Quebec, Hamilton, and surrounding areas. The stem cell therapy for Canada includes anywhere between 30 million and 200 million stem cells, with the treatments being administered by highly skilled doctors either by injection, intravenous, intrathecal, intramuscular or lymphatic.

The cost of stem cell therapy in Canada starts at only $2950 for 30 million cells, with an extra $1000 for 50 million cells. Exosomes are stem cell byproducts that have shown to be exceptionally beneficial when used in conjunction with stem cell therapies. The stem cell treatments and exosome therapies are performed at multiple Centers in Mexico, including Cancun, Tijuana and Mexicali.

All ground transportation is included, with VIP escorts from the airport and hotel to the clinic for the procedures. Each patients has a Personal Concierge Representative to assist with travel logistics and any questions during the process. Each patient undergoes a free virtual consultation with one of R3’s expert stem cell doctors.

According to R3 CEO David Greene, MD, MBA, “We worked very hard to ensure patients receive quality stem cell biologics with high cell counts for extremely affordable pricing. Our Centers are part of hospitals, surgery centers or medical complexes in order to make sure the most contemporary resources are available.”

Currently, almost half of R3’s patient base internationally comes from referrals and repeat patients. "That really says a lot about how successful the stem cell procedures are for patients. The kids with autism, the patients with kidney or lung issues and those with diabetes are often so happy they send in their friends!" added Dr. Greene.

For those in Canada interested in stem cell therapy, call R3 today to set up a free phone consultation at +1 (888) 988-0515 or visit the website at https://r3stemcell.com/canada for more information.

David Greene, MD, MBA
R3 Stem Cell International
+1 888-988-0515
email us here


Source: EIN Presswire